US journal in row over sponsored supplementBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7562.277-a (Published 03 August 2006) Cite this as: BMJ 2006;333:277
- Fred Charatan
The American Journal of Cardiology is at the centre of a publication ethics row after publishing a supplement sponsored by the drug company Pfizer funded for $55 800 (£29 900; €43 700). The supplement contained recommendations for screening that were not only of dubious clinical worth but would have had huge financial implications for the US health budget.
Pfizer manufactures the cholesterol treatment atorvastatin (Lipitor). The supplement suggested screening asymptomatic older US men and women for evidence of coronary artery calcium, using computed axial tomography scans, and carotid intima media thickness and plaque using ultrasonography (BMJ 2006;333: 168, 22 Jul).
The US …